Search clinical trials for: Stage IV Head and Neck Squamous Cell Carcinoma

Total 475715 results

National Cancer Institute (NCI)

Completed

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Boston Medical Center
United States Department of Defense

Completed

Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

Head and Neck Cancer

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Terminated

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

Pain | Head and Neck Cancer | Mucositis | Radiation Toxicity

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Comprehensive Cancer Network

Completed

Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

Gastric Adenocarcinoma | Recurrent Gastric Carcinoma | Esophageal Undifferentiated Carcinoma | Gastric Squamous Cell Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IV Esophageal Adenocarcinoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Nasopharynx | Stage IV Squamous Cell Carcinoma of the Nasopharynx

United States, Singapore, China
Mayo Clinic
National Cancer Institute (NCI)

Completed

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Recurrent Skin Carcinoma | Stage III Renal Cell Cancer | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Non-Small Cell Lung Carcinoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IV... and other conditions

United States
Gruppo Oncologico del Nord-Ovest

Unknown

Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin (INTERCEPTOR)

Squamous Cell Carcinoma of the Head and Neck

Italy
Shanghai Jiao Tong University School of Medicine

Completed

TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage III Oral Cavity Squamous Cell Carcinoma

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Completed

Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Withdrawn

CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy

Pain | Head and Neck Cancer | Oral Complications of Radiation Therapy | Weight Changes
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871

Breast Cancer | Head and Neck Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Head and Neck Cancer | Dysphagia | Mucositis | Xerostomia

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Head and Neck Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Head and Neck Cancer | Carcinoma of Unknown Primary

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Head and Neck Cancer

Head and Neck Cancer
University of Washington
National Cancer Institute (NCI)

Terminated

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

Nausea and Vomiting | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Nasopharynx | Stage III Squamous Cell Carcinoma of the Oropharynx and other conditions

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer

Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial

Head and Neck Cancer
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy

Head and Neck Cancer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Head and Neck Cancer
National Cancer Institute (NCI)

Terminated

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditions

Canada
National Cancer Institute (NCI)

Withdrawn

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Head and Neck Cancer

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Genentech, Inc.

Completed

Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer

Head and Neck Cancer

United States
National Cancer Institute (NCI)

Terminated

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditions

Canada, United States
National Cancer Institute (NCI)

Completed

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (MAESTRO HN)

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditions

United States, China
National Cancer Institute (NCI)

Completed

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Recurrent Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma

United States
Vanderbilt University Medical Center
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

Head and Neck Cancer

United States
Vanderbilt University Medical Center
National Cancer Institute (NCI)

Completed

Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer

Head and Neck Cancer

United States
Vanderbilt University Medical Center
National Cancer Institute (NCI)

Completed

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

Head and Neck Cancer

United States
National Cancer Institute (NCI)

Completed

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma... and other conditions

Canada
Quynh-Thu Le
GlaxoSmithKline

Terminated

Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Head and Neck Cancer | Carcinoma, Squamous Cell | Head and Neck Cancers

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Sanofi-Synthelabo

Terminated

Title XELOX FOR SALIVARY GLAND CANCERS

Head and Neck Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

Head and Neck Cancer | Radiation Toxicity | Oral Complications of Radiation Therapy

United States
University of Miami

Completed

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract

Head and Neck Cancer | Precancerous/Nonmalignant Condition

United States
National Cancer Institute (NCI)

Completed

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

Recurrent Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Positron Emission Tomography in Determining Stage of Esophageal Cancer

Esophageal Cancer

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

High-dose ICE With Amifostine

Sarcoma | Kidney Cancer | Testicular Germ Cell Tumor | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Bladder Cancer | Extragonadal Germ Cell Tumor | Carcinoma of Unknown Primary

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

Head and Neck Cancer

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck

Head and Neck Cancer

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); AstraZeneca; MedImmune LLC

Completed

Randomized Amifostine For SCCHN

Head and Neck Cancer | Mucositis | Xerostomia | Radiation Toxicity | Chemotherapeutic Agent Toxicity

United States
University of Miami

Completed

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Head and Neck Cancer | Infection | Oral Complications

United States
University of Miami

Completed

Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer

Head and Neck Cancer | Carcinoma of Unknown Primary

United States

Search clinical trials for: Stage IV Head and Neck Squamous Cell Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations